Metabolism, Inborn Errors
Metabolic·MeSH: Metabolism, Inborn Errors
Prevalence
5.0 / 100K
1 drug in development·1 company·5 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| mipomersen | TG THERAPEUTICS, INC. (TGTX) |
Frequently asked questions
How many drugs are in development for Metabolism, Inborn Errors?
BioSniper tracks 1 drug in development for Metabolism, Inborn Errors across 1 company.
How many clinical trials target Metabolism, Inborn Errors?
There are 5 clinical trials targeting Metabolism, Inborn Errors tracked by BioSniper.
What is the prevalence of Metabolism, Inborn Errors?
The estimated prevalence of Metabolism, Inborn Errors is approximately 5.0 per 100,000 population.
Deep-dive into Metabolism, Inborn Errors
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis